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Abstract. Surfactant-associated protein (SP-A) was mea- 
sured in tracheal aspirates of ventilated infants with (n = 
51) and without (n = 21) respiratory distress syndrome 
(RDS). SP-A concentrations in samples collected after 
birth were significantly lower in RDS than in infants ven- 
tilated for other reasons than RDS (median 0.03 vs. 1.60 
gg/ml). As a biochemical test to diagnose RDS early 
after birth, the sensitivity of measuring SP-A in tracheal 
aspirates was 87% and specificity 81%. SP-A content in 
tracheal aspirates of infants with RDS was monitored 
during the first 7 days of life. A significant (P < 0.001) 
increase within the first 4 days was found in those infants 
who survived, whereas no such change was found in 
those infants who died. 
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Introduction 
The surfactant-associated protein (SP-A) (MW 28-36000), 
secreted by type I I  alveolar cells is developmentally reg- 
ulated. Its concentration i amniotic fluid increases dur- 
ing the third trimester of gestation parallelling the in- 
crease in surfactant phospholipids during that period [7, 
13, 23], Measurement of the SP-A concentration i am- 
niotic fluid has therefore been used to assess lung matur- 
ity [11, 12, 14, 22]. 
After birth, an estimate of its concentration i the al- 
veoli could help distinguish between true respiratory dis- 
tress syndrome of the premature [i.e. primary surfactant 
deficiency, respiratory distress syndrome (RDS)] and 
other clinical entities, which can mimic RDS, such as 
connatal pneumonia, Group B-streptococcal disease, pul- 
monary maladaptation a d shock lung [8]. Knowledge of 
its concentration might be useful for the understanding 
of lung abnormality in RDS and of lung repair after such 
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injury. It might also be possible to predict the course of 
RDS, whether the baby will recover, will develop chron- 
ic lung disease, or even die [16]. 
The purpose of our study was to use an enzyme-linked 
immunoassay (ELISA) as a biochemical tool in addition 
to clinical and radiological criteria for the diagnosis of 
RDS. We postulated that differences in the outcome 
from RDS are reflected in the SP-A content of tracheal 
aspirates in the first 7 days after birth. 
Patients and methods 
Patients 
We studied 51 consecutive ventilated infants with RDS (RDS 
group) and 21 consecutive infants who were ventilated for reasons 
other than RDS (non-RDS group) in the same period. Reasons for 
ventilation in the non-RDS group included: sepsis/connatal infec- 
tion (n =7); wet lung disease (n = 3); chromosomal berrations 
(n = 2); persistent fetal circulation (n = 1); meconium aspiration 
(n = 1); perinatal asphyxia (n = 2). 
Diagnoses were made within the first 6 h after birth. Unless the 
babies had overt connatal infection, we included in the "RDS" 
group all babies with a clinical and roentgenological picture consis- 
tent with RDS, using the criteria of Hjalmarson [9]. Connatal in- 
fection was diagnosed if two out of the following three criteria 
were fulfilled: (1) positive blood cultures or swabs at birth; (2) im- 
mature to total neutrophils ratio ->0.20; (3) C-reactive protein 
concentration at birth > I mg/dl. All diagnoses were made at the 
bedside without knowledge of the results of the tracheal aspirate 
studies, and for this study were not revised. Tracheal aspirates 
were sampled at intubation and subsequently in the 1st week of life 
during routine airway suctioning after instillation of 1 ml physio- 
logical saline. In addition gastric aspirates of healthy mature in- 
fants (> 36 weeks of gestation) were collected at birth (normal 
group). Samples were frozen at -20~ until assayed. 
Surfactant substitution. Surfactant treatment in RDS was carried 
out as a clinical trial using Curosurf, a semi-natural surfactant of 
porcine origin, which does not contain SP-A [4]. Details of the trial 
are published elsewhere [21]. 
Biochemical analysis 
Anti-human surfactant protein A antibodies (rabbit polyclonal and 
mouse monoclonal) and human recombinant SP-A were a gracious 
gift from Byk Gulden, Konstanz, Federal Republic of Germany. 
ELISA. A non-competitive "sandwich" immunoassay, similar to 
[14], using a monoclonal anti-human SP-A antibody as the first 
and a polyclonal anti-human SP-A antibody as the second anti- 
body was set up. 100 btl of standards and samples, diluted in 10 mM 
Tris, 150 mM NaC1, 0.05% Tween 20 were applied. Standard rows 
ranging from i ng/ml to 1 gg/mI as well as a blank (dilution buffer) 
were run on each plate. Each sample was diluted 1:100 and 1: 
2000. The third antibody was a peroxidase-conjugated goat anti- 
rabbit (IgG) antibody. Optical density was read at 492 nm. 
Additional methods. For determination of total protein the Bio- 
Rad Protein Assay (Bio-Rad, Richmond, Ca) was used with bo- 
vine serum albumin as standard. Phospholipid content was mea- 
sured using the method according to Bartlett [1] after lipid extrac- 
tion [2]. 
Statistics. For statistical comparisons the chi-square t st, the Mann- 
Whitney test for non-parametric data and Friedman's analysis of 
variance were used. Since the source of the sample in the normal 
group (gastric aspirate) was different from that of both other groups 
(tracheal aspirate), no comparative statistics were done using the 
data from the normal group. The results are included only to illus- 
trate the normal range of values at term. 
In the RDS as well as the non-RDS group the number of cases 
decreased with time due to patient recovery or death. Therefore, 
in order to compare the course of the SP-A concentrations with 
time in these groups with varying cell numbers, the following two 
techniques were applied: 
1. For each individual the value at day 1 was subtracted from val- 
ues at subsequent days after birth (e.g. day 2-day 1, day 3-day 1, 
etc.). At each time point, the residuals in the RDS groups were 
then compared to those in the non-RDS group by the Mann-Whit- 
ney test with Bonferoni's adjustment for multiple comparisons 
applied. This procedure issubsequently called: A-d1. 
2. For each individual values at a particular time point were sub- 
tracted from the value at the next day. The resulting differences 
were then compared between the RDS and non-RDS groups by 
the Mann-Whitney test with Bonferoni's adjustment for multiple 
comparisons applied. This procedure issubsequently called: A-p. 
Results 
Validation of methods 
We have no absolutely reliable way of determining wheth- 
er the tracheal samples collected reflected alveolar con- 
tents. However, as mentioned before, SP-A is produced 
solely by the alveolar type II cell. Our results might also 
be biased by a dilution factor, depending on how much 
saline is reaspirated with tracheal suctioning and on the 
contribution of extra-alveolar secretions. Calculating the 
SP-A to total protein ratio helped to exclude samples in 
which only the instilled saline was recovered. However, 
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using this ratio did not yield more information than using 
SP-A concentrations alone. Chida et al. reported similar 
findings using surfactant protein/albumin ratios [3]. No 
correlation was found between the concentration of SP- 
A in the sample and the volume of the sample. For the 
purposes of this paper, only the results from the SP-A 
concentration measurements are therefore presented. 
The intra-assay coefficients of variation, calculated 
by comparing the results of 12 standard rows on one 
plate, were 0.16 for lng/ml,  0.11 for 5ng/ml, 0.16 for 
10 ng/ml and 0.07 for 50 ng/ml. The between-assay coef- 
ficients of variation, calculated by comparing the results 
of 12 standard rows on 12 plates assayed in a period of 4 
months, were 0.29 for i ng/ml, 0.21 for 5 ng/ml, 0.18 for 
10 ng/ml and 0.14 for 50 ng/ml. 
Patients 
Fifty-one infants fulfilled clinical and roentgenological 
criteria for RDS (RDS group) and 17 infants in this group 
were treated with exogenous surfactant. Twenty-one in- 
fants were ventilated for reasons other than RDS (non- 
RDS group). 
Non-RDS infants were more mature and weighed 
more than RDS infants. The proportion of infants treated 
antenatally with lung maturation-stimulating drugs was 
lower in the non-RDS group than in the infants with 
RDS (3/16 vs. 20/51). 
Thirteen infants with RDS died, 4 of these within the 
1st week of life. In the surfactant-treated subgroup, 2/17 
infants died, both after the 1st week of life. Of the in- 
fants with RDS who had not been treated with surfac- 
tant, 11/34 died (4 in the 1st week of life). Of the 21 in- 
fants in the non-RDS group, 4 died, one of these within 
the 1st week of life. 
Measurements 
As shown in Table 1, SP-A values on the 1st day of life 
in neonates with RDS were significantly lower than in 
ventilated newborns without RDS (P < 0.001). In Fig. 1 
the distribution of the SP-A concentrations in tracheal 
aspirates at birth of infants with RDS and without RDS 
is shown. 
Data from a previous tudy by Gerdes et al. suggest- 
ed that artificial ventilaton by itself could have increased 
Table 1. Biochemical nalysis of the 
tracheal aspirate contents at birth 
SP-A 
(gg/ml) 
Total protein 
(mg/ml) 
Phospholid 
(mg/ml) 
SP-A/protein ratio 
(gg/mg) 
*P< 0.001; **P< 0.002 
RDS Non-RDS Normal 
0.03 * 1.60 6.96 
(0 - 2.52) (0 -42.19) (0.15-98.36) 
0.56 0.89 3.38 
(0.02-10.32) (0.07- 2.34) (1.47- 5.84) 
0.02 0.17 0.25 
(0 - 8.13) (0 - 4.23) (0.03- 0.68) 
0.1 ** 1.83 27.43 
(0 - 2.03) (0 -28.88) (0.1 -27.94) 
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Fig. 1. SP-A concentrations in tracheal aspirates 
on the first day of life in 38 infants with RDS 
(RDS) compared to those in 16 ventilated infants 
without RDS (non-RDS), The Y-axis has a 
logarithmic scale. The hatched line represents 
the cutoff value used for diagnosis of RDS 
(0.3 gg/ml). Median values are indicated by 
short horizontal lines 
Fig. 2. Receiver operating characteristics urve 
for tracheal aspirate SP-A concentrations in the 
diagnosis of RDS. The SP-A values (pg/ml) of 
chosen cutoff points are in parentheses 
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Fig. 3. Difference in SP-A values between day 1 and subsequent 
days in the 1st week of life in ventilated infants with RDS who sur- 
vived compared to infants with RDS who died. The dotted line 
serves to illustrate zero difference, i.e. no change in SP-A concen- 
trations in tracheal aspirate between agiven day and day 1 (birth) 
alveolar SP-A concentrations to values above those found 
on the 1st day of life in similar infants without artificial 
ventilation [6]. For this graph and the design of the diag- 
nostic test, we therefore used only the results from sam- 
ples collected immediately after birth (38 in the RDS 
group, 16 in the non-RDS group). We constructed a Re- 
ceiver Operating Characteristics curve, and graphically 
determined the point at which the optimal combination 
of sensitivity and specificity was obtained (Fig. 2). With 
a cutoff value of 0.3 ~tg/ml SP-A in tracheal aspirate, 33 
cases (87%) in the RDS group were below and 5 (13%) 
values above the cutoff point. In the non-RDS group 
there were 3 (19%) values below and 13 values (81%) 
above the cutoff point. This difference, calculated with 
the chi-square test with continuity correction for small 
numbers, was significant at P < 0.0001. 
The course of SP-A concentration i tracheal aspi- 
rates was followed during the 1st week of life. In infants 
who recovered from RDS there was a gradual but signif- 
icant increase in SP-A concentrations during the first 4 
days of life to levels similar to those in infants without 
RDS (Friedman's analysis of variance, P < 0.001). In in- 
fants who did not survive, the SP-A concentrations stayed 
low - in most cases below the cutoff value - and never 
reached normal evels. In the non-RDS group SP-A levels 
varied from day to day and from patient o patient, but 
no trend was detectable. The infants in this group who 
died had SP-A levels above the cutoff point. 
As can be seen in Fig. 3, calculation of the A-d1 pro- 
cedure showed that SP-A values in infants with RDS 
who survived had significantly increased by day 4 (day 4- 
1, P < 0.005) and 5 (day 5-1, P < 0.002) of life. Because 
the increases were very gradual, the A-p procedure did 
not show significant differences between the two groups. 
In comparison, SP-A concentrations in infants who died 
did not change significantly in the 1st week of life. 
No difference in SP-A content was found between in- 
fants who were treated with surfactant and infants with- 
out surfactant treatment at any time during the first days 
of life (results not shown). 
No difference was found in SP-A values between male 
and female infants in both groups at any time after birth. 
Discuss ion  
Diagnosing RDS of prematurity and distinguishing it 
from other disease entities quickly and correctly is be- 
coming an important issue, now that surfactant substitu- 
tion is rapidly gaining acceptance as standard therapy for 
RDS. Investigators involved in the original surfactant 
substitution studies found that 40%-60% of the babies 
treated with surfactant for presumed primary RDS, had 
no RDS as defined by biochemical criteria [17]. 
A more accurate diagnosis of the cause of respiratory 
distress of the newborn might therefore help in predict- 
ing which infants will benefit from surfactant substitu- 
tion. 
A reliable assessment of lung maturity depends on 
the availability of a marker which is sufficiently specific 
for the aspect of lung development which is of interest. 
Most such clinically used tests depend on the increase 
with gestation in phospholipid content of amniotic fluid 
or gastric or tracheal aspirates at birth. In agreement 
with Chida et al. [3] our study shows that the concentra- 
tion of pulmonary surfactant-associated protein SP-A in 
tracheal aspirate is another reliable indicator of lung 
maturity. In contrast to most tests using surfactant phos- 
pholipid component, which could be contaminated with 
exogenous phospholipids (e.g. cell membranes, etc.) [5, 
10, 20], the SP-A assay system is more surfactant-specif- 
ic and will detect such small amounts to be clinically use- 
ful even with small samples obtained from very low birth 
weight infants. 
Table 2. Clinical data of the patients 
RDS non-RDS Normal 
(n = 51) (n = 21) (n = 26) 
Gestational ge 29 36 
(weeks) (26-36) (25-43) 
Mean birth weight 1185 2303 
(g) (570-2640) (700-4100) 
Female 26 6 
Male 25 10 
Umbilical artery pH 7.29 7.26 
(6.7-7.43) (6.92-7.35) 
Antenatal drugs 20 3 
4O 
38-42) 
3290 
2900-4040) 
10 
16 
7.29 
7.18-7.37) 
0 
Antenatal durgs: betamethasone or ambroxol given antenatally to 
stimulate lung maturation. Data are median and (minimum -
maximum) 
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tion, as reported by Lotze et al. [15], unsuccessful wean- 
ing correlated with lack of increase in SP-A concentra- 
tions with time. These results also parallel findings from 
immunostaining experiments in lungs of infants dying 
from RDS [16]. 
In conclusion, measuring the SP-A content in tracheal 
aspirates can be used as an additional, rapid and rela- 
tively reliable tool for the diagnosis of RDS. Its mea- 
surement could also help in assessing the eventual out- 
come of the pulmonary disease, since the SP-A concen- 
tration increases in the 1st week of life in those infants 
who will recover. In those infants who died, SP-A con- 
centrations remained low and never reached normal val- 
ues. Further studies are needed to elucidate the mecha- 
nism of the increase in recovering infants. 
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As expected, babies with RDS were smaller than 
those in the non-RDS group, which reflects their lower 
median gestational age (Table 2). However, differences 
in gestational age and birth weight only partially explain 
the difference in SP-A values found. Even after match- 
ing for gestational ge and/or birth weight, the non-RDS 
group had higher SP-A values than the RDS group (data 
not shown). As stated in methods, unless the babies had 
connatal infection, all babies which fulfilled clinical and 
roentgenological criteria for RDS were included in this 
group. Therefore, some infants which had disorders, 
such as pulmonary maladaptation, as defined by Hjal- 
marson [9], respiratory distress secondary to perinatal 
shock, etc., may have been included in the RDS group. 
These may account for some of the high SP-A values in 
this group. Conversely, some of the extremely low val- 
ues in the non-RDS group could be explained by the co- 
incidence of RDS and infection. 
Measurement of SP-A contents of tracheal aspirates 
has also broader interest as a possible parameter for 
monitoring wound healing in the lung. In surviving in- 
fants the increase in SP-A concentrations with time par- 
allels resolving RDS (Fig. 3). This can be explained by 
several possible mechanisms. Normal lung maturation 
might be accelerated in premature infants after birth. 
Factors associated with RDS might stimulate type II cells 
to start producing and secreting more surfactant. Nogee 
et al. found that the SP-A content of alveolar lavages 
and lung tissue of adult rats increased in response to hy- 
peroxia. They demonstrated that this was at least in part 
due to increased gene expression and protein synthesis 
[18, 19]. This might be a mechanism by which the lung 
tries to protect itself against he effects of oxygen injury. 
Another possible mechanism could be an alteration in 
the clearance of surfactant components from the alveo- 
lous as the alveolar epithelial barrier, which is leaky in 
the acute phase of the disease, becomes progressively 
tighter with time. 
The SP-A concentrations in infants with severe RDS 
who died, on the other hand did not increase. Similarly 
to the results after extracorporeal membrane oxygena- 
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